Company Product Description Indication Status Date

Phase I

Moderna Inc., of Cambridge, Mass. mRNA-1273 mRNA vaccine SARS-CoV-2  Dosed first participant in study being conducted by NIH 3/16/20

Phase II

Regeneron Pharmaceuticals Inc., of Tarrytown, N.Y., and Sanofi SA, of Paris  Kevzara (sarilumab) IL-6 receptor antagonist COVID-19 U.S. phase II/III trial initiated and will begin enrolling patients hospitalized with severe COVID-19 infection 3/16/20
Santen Pharmaceutical Co. Ltd., of Osaka, Japan, and Tracon Pharmaceuticals Inc., of San Diego DE-122 (carotuximab) Endoglin inhibitor  Wet age-related macular degeneration Discontinued development in wet AMD after top-line data indicated DE-122 did not improve visual acuity when combined with Lucentis (ranibizumab) as compared to single-agent Lucentis treatment 3/10/20

Phase III

Takeda Pharmaceutical Co. Ltd., of Osaka, Japan Ninlaro (ixazomib) Oral proteasome inhibitor Multiple myeloma Addition of ixazomib to lenalidomide and dexamethasone in Tourmaline-MM2 trial resulted in an improvement in median progression-free survival of 13.5 months (p=0.073); but did not meet the threshold for statistical significance 3/10/20

Notes

The date indicated refers to the BioWorld Clinical data table in which the news item can be found.

For more information about individual companies and/or products, see Cortellis.

No Comments